Case Reports in Transplantation

Case Reports in Transplantation / 2013 / Article

Case Report | Open Access

Volume 2013 |Article ID 164016 |

Sumiko I. Armstead, Thomas Hellmark, Jorgen Wieslander, Xin J. Zhou, Ramesh Saxena, Nilum Rajora, "A Case of Alport Syndrome with Posttransplant Antiglomerular Basement Membrane Disease despite Negative Antiglomerular Basement Membrane Antibodies by EIA Treated with Plasmapheresis and Intravenous Immunoglobulin", Case Reports in Transplantation, vol. 2013, Article ID 164016, 5 pages, 2013.

A Case of Alport Syndrome with Posttransplant Antiglomerular Basement Membrane Disease despite Negative Antiglomerular Basement Membrane Antibodies by EIA Treated with Plasmapheresis and Intravenous Immunoglobulin

Academic Editor: R. L. Heilman
Received09 Jun 2013
Accepted17 Jul 2013
Published02 Dec 2013


Posttransplant antiglomerular basement membrane (anti-GBM) disease occurs in approximately 5% of Alport patients and usually ends in irreversible graft failure. Recent research has focused on characterizing the structure of the anti-GBM alloepitope. Here we present a case of a 22-year-old male with end-stage renal disease secondary to Alport syndrome, with a previously failed renal allograft, who received a second deceased-donor kidney transplant. Six days after transplantation, he developed acute kidney injury. The serum anti-GBM IgG was negative by enzyme immunoassay (EIA). On biopsy, he had crescentic glomerulonephritis with linear GBM fixation of IgG. With further analysis by western blotting, we were able to detect antibodies to an unidentified protein from the basement membrane. This patient was treated with plasmapheresis twice per week and monthly intravenous immunoglobulin (IVIG) for a total of five months. At the end of treatment, these unknown antibodies were no longer detected. His renal function improved, and he has not required dialysis. We conclude that anti-GBM disease in patients with Alport Syndrome may be caused by circulating antibodies to other components of the basement membrane that are undetectable by routine anti-GBM EIA and may respond to treatment with plasmapheresis and IVIG.

1. Introduction

Alport syndrome is a genetic disorder caused by mutations in COL4A3, COL4A4, and COL4A5 genes, impairing assembly of type IV collagen. Most cases are inherited in an x-linked pattern, although some cases are autosomal recessive and autosomal dominant [13]. Anti-GBM nephritis is usually associated with the presence of circulating IgG antibodies to the noncollagenous domain of alpha Type IV collagen, manifesting as linear IgG deposition along the GBM on immunofluorescence staining. These patients develop hematuria, proteinuria, and end-stage renal disease. Therapy is unsatisfactory and usually ends in graft failure [49]. When patients with Alport syndrome receive renal transplants, posttransplant anti-GBM nephritis occurs in 3–5% of patients [4, 5, 7]. Here we describe a case of Alport syndrome with development of posttransplant anti-GBM nephritis with negative anti-GBM antibodies by enzyme immunoassay (EIA) who was found to have circulating antibodies to another epitope at the noncollagenous region of type IV collagen. The patient was treated with plasmapheresis and IVIG and responded excellently with preservation of renal allograft function.

2. Case Report

A 22-year-old male with ESRD secondary to Alport syndrome presented for deceased donor kidney transplantation. The patient had previous kidney transplantation at age of 8 years and had acute T-cell mediated rejection 12 years later, requiring initiation of peritoneal dialysis. His other diagnoses included hypertension and hearing loss. His medications were prednisone, epoetin, potassium chloride, nephrovitamin, sevelamer, lisinopril, amlodipine, carvedilol, and paricalcitol. His mother and maternal grandfather also have Alport syndrome.

At presentation, he had no symptoms of infection or cardiovascular disease. The temperature was 37.5°C, blood pressure 120/70 mmHg, pulse 78 beats per minute, respiratory rate 16 breaths per minute, and oxygen saturation 100% on room air. His abdomen was nontender, and his exit site was perfect. The remainder of his physical exam was normal. His calculated panel reactive antibody was 86%. His BUN was 32 mg/dL, creatinine was 20.88 mg/dL, and serum bicarbonate was 30 mmol/L. The other electrolytes and complete blood count were unremarkable. Chest radiograph showed clear lungs and a normal heart and mediastinum.

The donor was a standard criteria donor with a 4 of 6 human leukocyte antigen mismatch. There was immediate graft function. Postoperative course is depicted in Figure 1. Immunosuppression included thymoglobulin (4 doses), mycophenolate, prednisone, and tacrolimus. His creatinine decreased from 20.88 mg/dL to 2.7 mg/dL by postoperative day (POD)6. On POD7, he developed gross hematuria and acute kidney injury (creatinine 3.1 mg/dL). Urinalysis revealed specific gravity 1.011, large blood, trace leukocyte esterase, 30 mg/dL protein, >720 red blood cells, 7 white blood cells, and 1 squamous epithelial cell. The serum anti-GBM IgG antibody was 0.3 units using multiplex flow immunoassay performed by the Mayo Clinic (≥1 is positive). The tacrolimus level was 4.1 ng/mL.

We performed a renal biopsy. Light microscopy (Figures 2(a) and 2(b)) showed fragments of cortex with 24 glomeruli, none globally sclerotic. One glomerulus revealed a small cellular crescent. Tubules were dilated with flattened epithelial cells, some with red blood cell casts. No tubulitis was present. Immunofluorescence microscopy showed linear staining along the capillary walls for IgG(3+) (Figure 2(c)) and kappa and lambda light chains (1~2+). There was segmental fine granular staining along the capillary walls for C3(2+). One glomerulus disclosed segmental necrosis and a small cellular crescent which stained for fibrinogen (Figure 2(d)). Peritubular capillaries were negative for C4d. Electron microscopy revealed one glomerulus with a cellular crescent. Occasional capillary tufts displayed focal foot process effacement. The diagnosis of posttransplant anti-GBM glomerulonephritis was rendered. The patient was immediately started on plasmapheresis with IVIG. The other immunosuppression was continued. After 5 sessions of plasmapheresis with IVIG, his creatinine was 4.1 mg/dL.

We then repeated renal biopsy. Light microscopy (Figure 2(e)) showed unremarkable glomeruli without crescents. There was significant acute tubular injury without tubulitis. Immunofluorescence microscopy showed linear staining of glomerular capillary walls with IgG(3+) and kappa and lambda light chains (1~2+). Electron microscopy was largely unremarkable.

Twice weekly plasmapheresis and monthly IVIG were continued for maintenance therapy. He had persistent hematuria; his creatinine decreased to 2.1 mg/dL. Renal biopsy was repeated on POD56. Light microscopy showed unremarkable glomeruli with focal mild tubular atrophy and interstitial fibrosis with patchy lymphoplasmacytic infiltrate (Figure 2(f)). Immunofluorescence microscopy showed linear staining along the capillary walls for IgG with much less intensity (2+) when compared to the two previous biopsies. Peritubular capillaries were negative for C4d. After 3 months of aggressive treatment, IVIG was discontinued, and the frequency of plasmapheresis was decreased to every 2 weeks. Plasmapheresis was discontinued after a total of 5 months; creatinine remained 2.1 mg/dL.

3. Immunoassay

As discussed above, the patient’s biopsy showed linear deposition of IgG along the GBM, consistent with anti-GBM nephritis; however, we failed to detect circulating anti-GBM antibody by routine EIA. As it is possible that this patient has antibody directed against an epitope on GBM that is not detected by standard EIA, we analyzed reactivity against recombinant noncollagenous (NC) domains of the , , and chains without finding any specific reactivity. To further explore the reactivity of the autoantibodies, we performed Western blotting using purified noncollagenous 1 domains and 6 M guanidine hydrochloride (GuHCl) extracts from basement preparations as reported in previous studies [5, 6]. We used the patient’s serum collected at specific time points: immediately prior to the second transplant and then at 1 week, 2 weeks, 2 months, 3 months, and 7 months after transplantation. Using the type IV collagen NC1 domains as antigen (Goodpasture antigen), despite the negative ELISA results, we found a weak reactivity to some of the samples. It must be stressed that the development time was much longer for the Alport samples (about 1 hour) compared to the Goodpasture sera (2 minutes); the experiment is not quantitative. There were, however, antibodies recognizing an unidentified protein from the 6 M GuHCl extract in each of the samples collected prior to transplantation and at 1 week, 2 weeks, 2 months, and 3 months after transplantation. These antibodies were no longer present at 7 months after transplantation (Figure 3).

4. Discussion

The glomerular basement membrane of patients with Alport syndrome lacks trimers. Posttransplant anti-GBM nephritis is an allogeneic response to antigens present in the transplanted kidney but absent in the native kidneys of the Alport recipient [7, 10, 11]. In x-linked Alport syndrome, target alloantibodies are to the noncollagenous 1 domain primarily [10]. Commercial assays are relatively insensitive to anti- antibodies [7].

Treatment of posttransplant anti-GBM disease in Alport syndrome remains a challenge. Recent characterization of anti-GBM autoepitopes and alloepitopes revealed differences in the supramolecular structure of the antigen and accessibility of the tissues [11, 12]. The alloepitope is more accessible within NC1 hexamers than the partially sequestered Goodpasture autoepitopes [13, 14]. A better understanding of the alloepitopes in posttransplant nephritis will help to create therapies to restore tolerance to the normal collagen [15].

In this case, we were unable to detect anti-GBM antibody using EIA, but very faint staining was found in Western blot analysis against bovine NC1 domain of type IV collagen identical to the classical Goodpasture pattern. This may indicate that the titers of circulating antibodies are below the detectable limit of EIA or that there are differences in fine specificity of these antibodies. We did, however, discover antibodies against other unidentified basement membrane protein(s) that were unique to the patient’s sera. Based on our results, we cannot say which anti-GBM antibodies are bound to the GBM, but the novel anti-GBM antibodies correlate better with disease progression. Further studies are needed to characterize this antigen.

Current treatment options include methylprednisolone pulse therapy, plasmapheresis, cyclophosphamide, mycophenolate, IVIG, and rituximab, and recent studies indicate bortezomib may be effective as well [7, 16, 17]. Graft failure approaches 90% regardless of the specific therapy used [7]. Here we describe a patient who responded to a combination of plasmapheresis and IVIG. To our knowledge, this combined therapy has not been previously reported in the treatment of posttransplant anti-GBM disease in Alport syndrome. We observed improvement in the patient’s renal function, and he has remained dialysis independent for 7 months after transplantation.


  1. Y. Pirson, “Making the diagnosis of Alport's syndrome,” Kidney International, vol. 56, no. 2, pp. 760–775, 1999. View at: Publisher Site | Google Scholar
  2. C. Pescucci, F. Mari, I. Longo et al., “Autosomal-dominant Alport syndrome: natural history of a disease due to COL4A3 or COL4A4 gene,” Kidney International, vol. 65, no. 5, pp. 1598–1603, 2004. View at: Publisher Site | Google Scholar
  3. I. Longo, P. Porcedda, F. Mari et al., “COL4A3/COL4A4 mutations: from familial hematuria to autosomal-dominant or recessive Alport syndrome,” Kidney International, vol. 61, no. 6, pp. 1947–1956, 2002. View at: Publisher Site | Google Scholar
  4. L. Berardinelli, E. Pozzoli, M. Raiteri et al., “Renal transplantation in Alport's syndrome. Personal experience in twelve patients,” Contributions to Nephrology, vol. 80, pp. 131–134, 1990. View at: Google Scholar
  5. J. Gobel, C. J. Olbricht, G. Offner et al., “Kidney transplantation in Alport's syndrome: long-term outcome and allograft anti-GBM nephritis,” Clinical Nephrology, vol. 38, no. 6, pp. 299–304, 1992. View at: Google Scholar
  6. V. L. P. W. J. d. Heuvel, C. H. Schroder, C. O. S. Savage et al., “The development of anti-glomerular basement membrane nephritis in two children with Alport's syndrome after renal transplantation: characterization of the antibody target,” Pediatric Nephrology, vol. 3, no. 4, pp. 406–413, 1989. View at: Google Scholar
  7. C. E. Kashtan, “Renal transplantation in patients with Alport syndrome,” Pediatric Transplantation, vol. 10, no. 6, pp. 651–657, 2006. View at: Publisher Site | Google Scholar
  8. M. J. Mojahedi, R. Hekmat, and H. Ahmadnia, “Kidney transplantation in patients with Alport syndrome,” Urology Journal, vol. 4, no. 4, pp. 234–237, 2007. View at: Google Scholar
  9. M. Sauter, H. Schmid, H. J. Anders, F. Heller, M. Weiss, and T. Sitter, “Loss of a renal graft due to recurrence of anti-GBM disease despite rituximab therapy,” Clinical Transplantation, vol. 23, no. 1, pp. 132–136, 2009. View at: Publisher Site | Google Scholar
  10. D. Brainwood, C. Kashtan, M. C. Gubler, and A. N. Turner, “Targets of alloantibodies in Alport anti-glomerular basement membrane disease after renal transplantation,” Kidney International, vol. 53, no. 3, pp. 762–766, 1998. View at: Publisher Site | Google Scholar
  11. D. Borza, “Autoepitopes and alloepitopes of type IV collagen: role in the molecular pathogenesis of anti-GBM antibody glomerulonephritis,” Nephron—Experimental Nephrology, vol. 106, no. 2, pp. e37–e43, 2007. View at: Publisher Site | Google Scholar
  12. B. G. Hudson, K. Tryggvason, M. Sundaramoorthy, and E. G. Neilson, “Alport's syndrome, Goodpasture's syndrome, and type IV collagen,” The New England Journal of Medicine, vol. 348, no. 25, pp. 2543–2556, 2003. View at: Publisher Site | Google Scholar
  13. X. P. Wang, A. B. Fogo, S. Colon et al., “Distinct epitopes for anti-glomerular basement membrane Alport alloantibodies and Goodpasture autoantibodies within the noncollagenous domain of α3(IV) collagen: a janus-faced antigen,” Journal of the American Society of Nephrology, vol. 16, no. 12, pp. 3563–3571, 2005. View at: Publisher Site | Google Scholar
  14. V. Pedchenko, O. Bondar, A. B. Fogo et al., “Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis,” The New England Journal of Medicine, vol. 363, no. 4, pp. 343–354, 2010. View at: Publisher Site | Google Scholar
  15. J. S. Kang, X. P. Wang, J. H. Miner et al., “Loss of α3/α4(IV) collagen from the glomerular basement membrane induces a strain-dependent isoform switch to α5α6(IV) collagen associated with longer renal survival in Col4a3-/- Alport mice,” Journal of the American Society of Nephrology, vol. 17, no. 7, pp. 1962–1969, 2006. View at: Publisher Site | Google Scholar
  16. G. Browne, P. A. J. Brown, C. R. V. Tomson et al., “Retransplantation in Alport post-transplant anti-GBM disease,” Kidney International, vol. 65, no. 2, pp. 675–681, 2004. View at: Publisher Site | Google Scholar
  17. R. Raghavan, A. Jeroudi, K. Achkar, A. O. Gaber, S. Patel, and A. Abdellatif, “Bortezomib in kidney transplantation,” Journal of Transplantation, vol. 2010, Article ID 698594, 6 pages, 2010. View at: Publisher Site | Google Scholar

Copyright © 2013 Sumiko I. Armstead et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

2381 Views | 644 Downloads | 0 Citations
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.